CoChat

Adeno-Associated Virus (AAV) Versus Immune Response

Open access

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Decades ago, Friedmann and Roblin postulated several barriers to gene therapy, including tissue targeting, delivery across the blood–brain barrier (BBB), and host immune responses. These issues remain pertinent till today. Since then, several advances have been made in elucidating structures of adeno-associated virus (AAV) serotypes, antibody epitopes, and ways to modify antibody-binding sites. AAVs capsid has also been engineered to re-direct tissue tropism, reduce ubiquitination, and promote passage across the BBB. Furthermore, the use of high(er) dose recombinant AAV (rAAV) has been accompanied by a better understanding of immune responses in both experimental animals and early clinical trials, and novel work is being performed to modulate the immune response. While the immune responses to rAAV remains a major challenge in translating experimental drugs to approved medicine, and will likely require more than a single solution, we now better understand the hurdles to formulate and test experimental solutions to surmount them.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/v11020102

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 This cartoon describes two risks associated with adeno-associated virus (AAV) entrance in to a target cell. The innate immune repsonse is activated by TLR9 recognition of the externalization of the viral genome. This event is rapid and NF-kB will be activated resulting in proiinflammatory cytokine production. For the many virions that do not rapidly uncoat, a second risk exists—the slow degradation of the capsid. Proteasomes degradation of ubiquitinated AAV results in a small amount of capsid fragments being transported through the transporter associated with antigen processing (TAP), into the endoplasmic reticulum (ER), and innevitable attachment to major histocompatibility complex (MHC) class I molecules. These peptides will be displayed on the cell surface and eventually recognized by cytotoxic T cells.
Figure 1 This cartoon describes two risks associated with adeno-associated virus (AAV) entrance in to a target cell. The innate immune repsonse is activated by TLR9 recognition of the externalization of the viral genome. This event is rapid and NF-kB will be activated resulting in proiinflammatory cytokine production. For the many virions that do not rapidly uncoat, a second risk exists—the slow degradation of the capsid. Proteasomes degradation of ubiquitinated AAV results in a small amount of capsid fragments being transported through the transporter associated with antigen processing (TAP), into the endoplasmic reticulum (ER), and innevitable attachment to major histocompatibility complex (MHC) class I molecules. These peptides will be displayed on the cell surface and eventually recognized by cytotoxic T cells.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

Metadata

Authors
Rabinowitz, J., Chan, Y. K., & Samulski, R. J.
Affiliations
  • Pfizer (United States) (US)
  • Harvard University (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
  • Rabinowitz, Joseph
  • Chan, Ying Kai
  • Samulski, Richard Jude
Venue
Viruses
Publisher
MDPI AG
Published
2019-01-25
Volume
11
Issue
2
Pages
102
ISSN
1999-4915 (ISSN-L)
OpenAlex
W2911711918
Cited by
122
References
54
Citations by year
2026: 4 · 2025: 12 · 2024: 14 · 2023: 16 · 2022: 17 · 2021: 29 · 2020: 24 · 2019: 6
FWCI
2.52
Type
journal article
Language
en
Open access
Locations
  • Viruses (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Heart, Lung, and Blood Institute (P01HL112761)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
adeno-associated virus, recombinant adeno-associated virus, gene therapy, immune response, AAV serotypes, capsid engineering, antibody epitopes, tissue tropism, blood-brain barrier, ubiquitination, immunomodulation, clinical translation
MeSH terms
Host Microbial Interactions, Dependovirus, Animals, Clinical Trials as Topic, Genetic Vectors, Humans, Immunity, Innate, Parvoviridae Infections, Genetic Therapy, Capsid Proteins, Mice, Adaptive Immunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.